Language:

Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England

Nature communications, 2021-12, Vol.12 (1), p.7217-7217, Article 7217 [Peer Reviewed Journal]

2021. Crown. ;Crown 2021. corrected publication 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Crown 2021, corrected publication 2022 ;ISSN: 2041-1723 ;EISSN: 2041-1723 ;DOI: 10.1038/s41467-021-27410-5 ;PMID: 34893611

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England
Author: Amirthalingam, Gayatri ; Bernal, Jamie Lopez ; Andrews, Nick J ; Whitaker, Heather ; Gower, Charlotte ; Stowe, Julia ; Tessier, Elise ; Subbarao, Sathyavani ; Ireland, Georgina ; Baawuah, Frances ; Linley, Ezra ; Warrener, Lenesha ; O'Brien, Michelle ; Whillock, Corinne ; Moss, Paul ; Ladhani, Shamez N ; Brown, Kevin E ; Ramsay, Mary E
Subjects: Age ; Aged ; Aged, 80 and over ; Antibodies ; Antibodies, Viral - blood ; Antibody Formation ; BNT162 Vaccine ; ChAdOx1 nCoV-19 ; Coronaviruses ; COVID-19 - prevention & control ; COVID-19 vaccines ; COVID-19 Vaccines - administration & dosage ; COVID-19 Vaccines - immunology ; England ; Female ; Humans ; Immunization Schedule ; Male ; Middle Aged ; Schedules ; Serology ; Vaccination ; Vaccine Efficacy ; Vaccines
Is Part Of: Nature communications, 2021-12, Vol.12 (1), p.7217-7217, Article 7217
Description: The UK prioritised delivery of the first dose of BNT162b2 (Pfizer/BioNTech) and AZD1222 (AstraZeneca) vaccines by extending the interval between doses up to 12 weeks. In 750 participants aged 50-89 years, we here compare serological responses after BNT162b2 and AZD1222 vaccination with varying dose intervals, and evaluate these against real-world national vaccine effectiveness (VE) estimates against COVID-19 in England. We show that antibody levels 14-35 days after dose two are higher in BNT162b2 recipients with an extended vaccine interval (65-84 days) compared with those vaccinated with a standard (19-29 days) interval. Following the extended schedule, antibody levels were 6-fold higher at 14-35 days post dose 2 for BNT162b2 than AZD1222. For both vaccines, VE was higher across all age-groups from 14 days after dose two compared to one dose, but the magnitude varied with dose interval. Higher dose two VE was observed with >6 week interval between BNT162b2 doses compared to the standard schedule. Our findings suggest higher effectiveness against infection using an extended vaccine schedule. Given global vaccine constraints these results are relevant to policymakers.
Publisher: England: Nature Publishing Group
Language: English
Identifier: ISSN: 2041-1723
EISSN: 2041-1723
DOI: 10.1038/s41467-021-27410-5
PMID: 34893611
Source: PubMed (Medline)
DAOJ: Directory of Open Access Journals
AUTh Library subscriptions: ProQuest Central
MEDLINE
Coronavirus Research Database

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England

Searching Remote Databases, Please Wait